Clinical Trials Arena on MSN16h
MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug
Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.
pharmaphorum2d
MSD gets first positive trial of Keytruda/Lynparza combo
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.
pharmaphorum5y
MSD’s Keytruda plus chemo backed by NICE for lung cancer
Merck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell lung cancer (NSCLC) as part of a regimen with chemotherapy, says NICE. Draft ...